Epidemiological trends and burden projections of childhood leukemia in China: age-stratified analysis and impact of COVID-19 from 1990 to 2035.
2/5 보강
OpenAlex 토픽 ·
Acute Lymphoblastic Leukemia research
COVID-19 and healthcare impacts
Childhood Cancer Survivors' Quality of Life
To analyze the incidence, mortality, and disease burden (disability-adjusted life year, DALY rate) of leukemia in children aged 0–14 years in China from 1990 to 2021.
APA
Limin Zhao, Haina Yao, et al. (2026). Epidemiological trends and burden projections of childhood leukemia in China: age-stratified analysis and impact of COVID-19 from 1990 to 2035.. Annals of hematology, 105(4). https://doi.org/10.1007/s00277-026-06799-3
MLA
Limin Zhao, et al.. "Epidemiological trends and burden projections of childhood leukemia in China: age-stratified analysis and impact of COVID-19 from 1990 to 2035.." Annals of hematology, vol. 105, no. 4, 2026.
PMID
41915223 ↗
Abstract 한글 요약
To analyze the incidence, mortality, and disease burden (disability-adjusted life year, DALY rate) of leukemia in children aged 0–14 years in China from 1990 to 2021. Based on the Chinese leukemia surveillance data in the Global Burden of Disease database from 1990 to 2021. The Estimated Annual Percentage Change (EAPC) and Bayesian Age–Period–Cohort (BAPC) prediction models were used to evaluate the trends of incidence, mortality and DALY in different strata and predict them to 2035. The EAPC was used to quantify the annual trends of incidence, mortality and DALY rates, and the BAPC model was used to decompose the independent effects of age, period and birth cohort on the burden of disease. The incidence of childhood leukemia in 2021 decreased by 10.8% compared with 1990, together with this, the mortality rate (76.9%) and DALY rate (76.9%) decreased significantly. After the COVID-19 pandemic, the incidence rates in the 1–5 month group and the 6–11 month group increased by 63.7% and 62.5%, respectively, while those in the 12–23 month group and the 2–4 year group decreased by 23.1% and 58.1%, respectively. Acute lymphocytic leukemia accounted for the highest proportion, and the incidence rate in male newborns was higher than that in female newborns. It is predicted that by 2035, the incidence, mortality and DALY rates will further decline. The burden of childhood leukemia is declining overall in China, but attention should be paid to fluctuations in specific age groups and gender differences to optimize early screening and classification treatment programs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Application of hair transplantation combined with platelet-rich plasma injection for the treatment of androgenic alopecia.
- Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
- A novel kinase inhibitor, Regorafenib, blocks EGFR-dependent signaling to repress tumour metastasis in human triple-negative breast cancers.
- Decoding the mechanical language of the tumor microenvironment: From physical forces to malignant behaviors.
- Prediction of solitary ≤3-cm small adrenal metastasis based on F-FDG PET/CT using a support vector machine model in lung cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAF Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.
- Associations of electronic health literacy with related factors in individuals diagnosed with colorectal cancer: a cross-sectional analysis.
- Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
- Construction and Validation of a Risk Prediction Model for Immune-Related Adverse Events in Lung Cancer Patients Receiving Immunosuppressants.
- Impact of COVID-19 pandemic on treatment patterns for stage I Non-Small Cell Lung Cancer in the Netherlands.